4Knaus WA, Zimmerman JE, Wagner DP, et al. APACHE -acute physiology, and chronic health evaluation:a physiologically based classification system [ J ]. Crit Care Med, 1981,9:591 - 597.
5汪复,吴永佩,张婴元,等.抗菌药物临床应用指导原则[M],2004,10:1-60.
6Behra-Miellet J,Dubreuil L,Jumas-Bilak E. Antianaerobic activity of moxitloxacin compared with that of ofloxacin, ciprofloxacin, clin- damyciu, metronidazole and beta - laetams [ J ]. Int J Antimierob Agents,2002,20 : 366 - 374.
7Chen DK, McGeer A, De Azavedo Jc, et al. Decreased susceptibility of streptococcus pneumoniae to fluoroquinolones in Canada[ J ]. N Engl J Med,1999,34-1:233 -239.
8Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among Gram-negative bacilli in US Intensive Care Units [ J ]. JAMA,2003,289 : 885 - 888.
9Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance:a report from the drug-resistant streptococcus pneumoniae therapeutic working group [ J]. Arch Intern Med, 2000, 160: 1399 - 1408.
10Blondeau JM, Hansen G, Metzler K, et al. The role of PK/PD parameters to avoid selection and increase of resistance: mutant provention concentration[ J]. J Chemother,200d., 16 : 1 - 19.
4Sivam S,Sciurba FC,Lucht LA,et al.Distribution of Pneu-mocystis jirovecii in lungs from colonized COPD patients[J].Diagnostic Microbiology and Infectious Disease,2011,71(1):24-28.
